<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768166</url>
  </required_header>
  <id_info>
    <org_study_id>TreatSPG11</org_study_id>
    <secondary_id>2019-002827-14</secondary_id>
    <nct_id>NCT04768166</nct_id>
  </id_info>
  <brief_title>Testing Miglustat Administration in Subjects With Spastic Paraplegia 11</brief_title>
  <acronym>TreatSPG11</acronym>
  <official_title>Phase 2 Pharmacological Trial to Evaluate the Safety of Miglustat Administration in Subjects With Spastic Paraplegia 11 (TreatSPG11)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Fondazione Stella Maris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Fondazione Stella Maris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary spastic paraparesis type 11 (SPG11) is caused by mutations in the SPG11 gene that&#xD;
      produces spatacsin, a protein involved in lysosomal function. Studies performed in skin cells&#xD;
      (fibroblasts) from SPG11 patients, mice and zebrafish models of the disease showed that the&#xD;
      material accumulated in the lysosomes is made of glycosphingolipids (GSL).&#xD;
&#xD;
      Miglustat is a drug that inhibits an enzyme called glucosylceramide synthetase (GCS) which is&#xD;
      used for the production of GSL. Miglustat, therefore, helps to delay the production of GSL.&#xD;
      This study aims to collect preliminary data on the safety of miglustat on the SPG11 disease&#xD;
      and to assess biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-Changes from baseline blood tests at 24 weeks 2-Changes from baseline neurophysiological tests at 24 weeks 3-Report of severe adverse events</measure>
    <time_frame>At baseline, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline GM2/GM3 levels at 24 weeks</measure>
    <time_frame>At baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess changes in the scores of the Spastic Paraplegia Rating Scale (SPRS) at 24 weeks</measure>
    <time_frame>At baseline, 24 weeks</time_frame>
    <description>SPRS rates disease severity (0-52) with lower numbers indicating less impairement</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hereditary Spastic Paraparesis</condition>
  <arm_group>
    <arm_group_label>Evaluate the safety of Miglustat administration in subjects with Spastic Paraplegia 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg of Miglustat, 3 caps per day for first 4 weeks; 100 mg of Miglustat, 6 caps per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miglustat</intervention_name>
    <description>Evaluate safety and tolerability of Miglustat in a group of subjects affected of SPG11.</description>
    <arm_group_label>Evaluate the safety of Miglustat administration in subjects with Spastic Paraplegia 11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written signed informed consent;&#xD;
&#xD;
          -  Confirmed diagnosis of SPG11;&#xD;
&#xD;
          -  Age &gt; 13 years;&#xD;
&#xD;
          -  SPRS score ≥ 10 or ≤35;&#xD;
&#xD;
          -  Use of effective contraceptive methods and the performance of pregnancy tests (only&#xD;
             fertile subjects).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of other concomitant neurodegenerative diseases;&#xD;
&#xD;
          -  Outcomes of severe pre- or peri-natal suffering;&#xD;
&#xD;
          -  Age ≤ 13 years;&#xD;
&#xD;
          -  SPRS score ≥ 35 or ≤10;&#xD;
&#xD;
          -  Hypersensitivity or intolerance to miglustat;&#xD;
&#xD;
          -  Participation in other pharmacological studies within 30 days of the first Study visit&#xD;
             (T0);&#xD;
&#xD;
          -  The inability to take the drug;&#xD;
&#xD;
          -  Any additional medical conditions;&#xD;
&#xD;
          -  Subjects with severe renal impairment;&#xD;
&#xD;
          -  Refusal to use effective contraceptive methods and the performance of pregnancy tests&#xD;
             (only fertile subjects).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo M Santorelli, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Stella Maris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippo M Santorelli, MD PhD</last_name>
    <phone>0039050886231</phone>
    <email>filippo3364@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Fondazione Stella Maris</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucrecia A Mota, D.M.L</last_name>
      <phone>0039050992140</phone>
      <email>lucreciaantonia.mota@fsm.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Ivana Ricca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bellofatto M, De Michele G, Iovino A, Filla A, Santorelli FM. Management of Hereditary Spastic Paraplegia: A Systematic Review of the Literature. Front Neurol. 2019 Jan 22;10:3. doi: 10.3389/fneur.2019.00003. eCollection 2019.</citation>
    <PMID>30723448</PMID>
  </reference>
  <reference>
    <citation>Boutry M, Branchu J, Lustremant C, Pujol C, Pernelle J, Matusiak R, Seyer A, Poirel M, Chu-Van E, Pierga A, Dobrenis K, Puech JP, Caillaud C, Durr A, Brice A, Colsch B, Mochel F, El Hachimi KH, Stevanin G, Darios F. Inhibition of Lysosome Membrane Recycling Causes Accumulation of Gangliosides that Contribute to Neurodegeneration. Cell Rep. 2018 Jun 26;23(13):3813-3826. doi: 10.1016/j.celrep.2018.05.098.</citation>
    <PMID>29949766</PMID>
  </reference>
  <reference>
    <citation>Branchu J, Boutry M, Sourd L, Depp M, Leone C, Corriger A, Vallucci M, Esteves T, Matusiak R, Dumont M, Muriel MP, Santorelli FM, Brice A, El Hachimi KH, Stevanin G, Darios F. Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration. Neurobiol Dis. 2017 Jun;102:21-37. doi: 10.1016/j.nbd.2017.02.007. Epub 2017 Feb 22.</citation>
    <PMID>28237315</PMID>
  </reference>
  <reference>
    <citation>Lo Giudice T, Lombardi F, Santorelli FM, Kawarai T, Orlacchio A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol. 2014 Nov;261:518-39. doi: 10.1016/j.expneurol.2014.06.011. Epub 2014 Jun 20. Review.</citation>
    <PMID>24954637</PMID>
  </reference>
  <reference>
    <citation>Platt FM, Jeyakumar M, Andersson U, Heare T, Dwek RA, Butters TD. Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):947-54. Review.</citation>
    <PMID>12803928</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Fondazione Stella Maris</investigator_affiliation>
    <investigator_full_name>Filippo Maria Santorelli</investigator_full_name>
    <investigator_title>Director Molecular Medicine, Neurogenetics and Neuromuscular Disorders</investigator_title>
  </responsible_party>
  <keyword>Autophagic Lysosome Reformation</keyword>
  <keyword>SPG11</keyword>
  <keyword>Miglustat</keyword>
  <keyword>Lisosomal Storage Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Paraparesis</mesh_term>
    <mesh_term>Paraparesis, Spastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

